Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.67 |
| ▸ | PTGES | O14684 | 2/20 | 0.60 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188273 | 0.93 | PPARG (1.00) | PPARGCYP2C8PTGESPPARANR1I2 | |
| SCHEMBL7131095 | 0.81 | PPARG (0.70) | PPARGCYP2C8PPARACYP3A4ALOX15 | |
| SCHEMBL27188277 | 0.80 | PPARG (1.00) | PPARGCYP2C8PPARANR1I2PPARD | |
| SCHEMBL27188313 | 0.79 | PPARG (0.63) | PPARGPTGESSMN1; SMN2 | |
| SCHEMBL29113778 | 0.78 | KMT2A (0.74) | PPARGCYP2C8PPARACYP3A4ALOX15 | |
| SCHEMBL14840973 | 0.77 | PPARG (0.78) | PPARGCYP2C8PPARANR1I2PPARD | |
| SCHEMBL17199177 | 0.75 | PTGES (1.00) | PPARGPTGES | |
| SCHEMBL7128796 | 0.74 | PPARG (0.70) | PPARGCYP2C8PPARACYP3A4ALOX15 | |
| SCHEMBL7121705 | 0.73 | RORC (0.80) | PPARGPPARACYP3A4ALOX15MAPK1 | |
| SCHEMBL7118637 | 0.73 | KMT2A (0.58) | PPARGCYP2C8PPARACYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109850-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | claimed |
| US-20240109850-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109850-A1 | Covalent PPARG inverse-agonists | PPARG, PPARD, PPARA | PPARG 1/4885CYP2C8 839/4885PTGES 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.